INmune Bio, Inc. (NASDAQ:INMB) CEO Acquires $98,124.40 in Stock

INmune Bio, Inc. (NASDAQ:INMB) CEO Raymond Joseph Tesi purchased 15,380 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were purchased at an average price of $6.38 per share, for a total transaction of $98,124.40. Following the acquisition, the chief executive officer now owns 1,554,106 shares of the company’s stock, valued at $9,915,196.28. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

INmune Bio Price Performance

Shares of INMB stock opened at $5.19 on Thursday. The company has a market capitalization of $102.67 million, a price-to-earnings ratio of -2.70 and a beta of 1.86. INmune Bio, Inc. has a one year low of $5.18 and a one year high of $14.74. The company’s fifty day moving average price is $7.28 and its 200-day moving average price is $9.12.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 103.56%.

Analysts Set New Price Targets

Separately, Scotiabank initiated coverage on shares of INmune Bio in a report on Thursday, August 22nd. They set a “sector outperform” rating and a $22.00 price target on the stock.

Institutional Trading of INmune Bio

Several institutional investors and hedge funds have recently modified their holdings of INMB. CVI Holdings LLC bought a new stake in shares of INmune Bio during the 2nd quarter valued at $5,260,000. Marshall Wace LLP raised its position in shares of INmune Bio by 332.1% during the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock valued at $1,022,000 after purchasing an additional 89,091 shares during the period. Bank of New York Mellon Corp raised its position in shares of INmune Bio by 124.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock valued at $517,000 after purchasing an additional 32,511 shares during the period. Rhumbline Advisers purchased a new position in INmune Bio during the second quarter valued at $121,000. Finally, Westside Investment Management Inc. grew its stake in INmune Bio by 31.8% during the second quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock valued at $400,000 after acquiring an additional 10,950 shares in the last quarter. 12.72% of the stock is currently owned by institutional investors.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.